Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gross Profit: 2010-2025

Historic Gross Profit for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $3.7 million.

  • Lineage Cell Therapeutics' Gross Profit fell 1.74% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 27.76%. This contributed to the annual value of $9.2 million for FY2024, which is 10.77% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Gross Profit stood at $3.7 million for Q3 2025, which was up 34.85% from $2.7 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Gross Profit high stood at $5.1 million for Q1 2022, and its period low was $279,000 during Q1 2021.
  • Its 3-year average for Gross Profit is $2.3 million, with a median of $2.3 million in 2023.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Gross Profit soared by 1,713.98% in 2022, and later tumbled by 61.02% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Gross Profit (Quarterly) stood at $964,000 in 2021, then skyrocketed by 88.07% to $1.8 million in 2022, then grew by 1.05% to $1.8 million in 2023, then surged by 48.14% to $2.7 million in 2024, then dropped by 1.74% to $3.7 million in 2025.
  • Its Gross Profit was $3.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $1.5 million in Q1 2025.